(Reuters) -Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
The company said patients who took its experimental drug favezelimab in combination with Keytruda did not show significant improvement in overall survival compared to standard-of-care treatment.
The combination therapy is also being evaluated as a treatment for certain blood disorders and solid tumors.
(Reporting by Christy Santhosh; Editing by Varun H K and Shilpi Majumdar)
Source link : https://www.medscape.com/s/viewarticle/mercks-colorectal-cancer-therapy-fails-late-stage-trial-2024a1000hej?src=rss
Author :
Publish date : 2024-09-25 10:58:52
Copyright for syndicated content belongs to the linked Source.